Claims for Patent: 9,265,652
✉ Email this page to a colleague
Summary for Patent: 9,265,652
| Title: | Intrauterine contraceptive device |
| Abstract: | A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device. |
| Inventor(s): | Michael Tal, Bob H. Katz, Mark James DeBisschop, Pete Wilson, Oleg Shikhman |
| Assignee: | Sebela Vlc Ltd |
| Application Number: | US13/585,039 |
| Patent Claims: |
1. A method for promoting contraception by placing a contraceptive device within a uterus without blocking openings of two fallopian tubes, the method comprising: advancing a tapered distal end of a delivery sheath through a cervix and into the uterus, with the contraceptive device preloaded into and completely contained within the delivery sheath; at least one of retracting the sheath or advancing a pusher member disposed within the sheath to advance the contraceptive device comprising an elongate shape memory member out of the tapered distal end of the delivery sheath and into the uterus, thus causing the contraceptive device to expand from a first, compressed shape within the delivery sheath to a second, expanded shape within the uterus, wherein two tissue contact surfaces at opposite ends of the shape memory member contact an inner wall of the uterus below and not within the openings of the two fallopian tubes when the contraceptive device is in the second shape, and wherein each of the tissue contact members, when the contraceptive device is delivered, is positioned near, but not within, an opening of one of the two fallopian tubes branching from the uterus, wherein the elongate shape memory member of the contraceptive device comprises: a spring portion formed as a loop at a bottom of the contraceptive device, configured to provide outwardly directed force to the tissue contact surfaces to prevent them from migrating down the inner wall of the uterus, two middle portions of the elongate member extending vertically upward from the spring portion, two bends in the elongate member that cause the elongate member to cross over itself at a top of the middle portions, two arm portions extending laterally outward from the two bends to the two tissue contact surfaces, and the two tissue contact surfaces, each of which is formed as a loop in one of the opposite ends of the elongate shape memory member; and delivering copper from the contraceptive device into the uterus, wherein the contraceptive device further comprises: at least one copper sleeve disposed over each of the two middle portions at or near the spring portion, and at least one copper sleeve disposed over each of the two arm portions at or near the two tissue contact surfaces. 2. A method as in claim 1, wherein each of the tissue contact surfaces, when the device is delivered, is positioned within approximately 2 cm of an opening one of the openings of one of the two fallopian tubes. 3. A method as in claim 1, further comprising delivering an additional substance within the uterus via the contraceptive device, wherein the additional substance is selected from the group consisting of hormones, spermicides and therapeutic agents. 4. A method as in claim 1, wherein a total exposed surface area of all of the copper sleeves of the contraceptive device is no more than about 200 square millimeters. 5. A method as in claim 1, further comprising removing the contraceptive device through the cervix by pulling on a thread connected to the contraceptive device. 6. A method as in claim 1, wherein advancing the contraceptive device out of the delivery device comprises delivering the contraceptive device to a first, inferior location in the uterus, and wherein the method further comprises allowing the contraceptive device to migrate superiorly to a second location in the uterus after delivery, wherein the second location is below the openings of the two fallopian tubes. 7. A method for promoting contraception by focally delivering a substance within a uterus without blocking openings of two fallopian tubes, the method comprising: advancing a tapered distal end of a delivery sheath through a cervix and into the uterus, with the contraceptive device preloaded into and completely contained within the delivery sheath; at least one of retracting the sheath or advancing a pusher member disposed within the sheath to advance a contraceptive device comprising an elongate shape memory member out of the tapered distal end of the delivery sheath and into the uterus, thus causing the contraceptive device to expand from a first, compressed shape within the delivery sheath to a second, expanded shape within the uterus, wherein two tissue contact surfaces at opposite ends of the shape memory member contact an inner wall of the uterus below and not within the openings of the two fallopian tubes when the contraceptive device is in the second shape, and wherein each of the tissue contact members, when the contraceptive device is delivered, is positioned near, but not within, an opening of one of the two fallopian tubes branching from the uterus, wherein the elongate shape memory member of the contraceptive device comprises: a spring portion formed as a loop at a bottom of the contraceptive device, configured to provide outwardly directed force to the tissue contact surfaces to prevent them from migrating down the inner wall of the uterus, two middle portions of the elongate member extending vertically upward from the spring portion, two bends in the elongate member that cause the elongate member to cross over itself at a top of the middle portions, two arm portions extending laterally outward from the two bends to the two tissue contact surfaces, and the two tissue contact surfaces, each of which is formed as a loop in one of the opposite ends of the elongate shape memory member; and delivering the substance to at least one targeted area of the uterus over time, via the contraceptive device, wherein the substance comprises copper, wherein the at least one targeted area includes areas at or near both of the fallopian tube openings and an area at or near a cervical os, and wherein the contraceptive device further comprises: at least one copper sleeve disposed over each of the two middle portions at or near the spring portion, and at least one copper sleeve disposed over each of the two arm portions at or near the two tissue contact surfaces; and allowing the elongate shape memory member of the contraceptive device to partially collapse within the uterus such that the copper sleeves disposed over the two arm portions form a continuous line across the uterus between the two tissue contact surfaces. 8. A method as in claim 7, wherein a total exposed surface area of all of the copper sleeves is no more than about 200 square millimeters. 9. A method as in claim 7, wherein, when the elongate shape memory member of the contraceptive device is partially collapsed, the copper sleeves disposed over the two arm portions form an approximately continuous cylinder. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
